Evidence map›Paper›PMID 26451308›Full record

ArticleOncoimmunology2015

Therapeutic potential of interleukin-27 against cancers in preclinical mouse models.

Izuru Mizoguchi, Yukino Chiba, Jun-Ichi Furusawa, Mingli Xu, Ren Tsunoda, Kaname Higuchi, Takayuki Yoshimoto

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Natural and Engineered Cytokines as Cancer Therapeutics.Annual review of cancer biology · 2026
    Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Izuru MizoguchiDepartment of Immunoregulation; Institute of Medical Science; Tokyo Medical University ; Tokyo, Japan.
Yukino ChibaDepartment of Immunoregulation; Institute of Medical Science; Tokyo Medical University ; Tokyo, Japan.
Jun-Ichi FurusawaDepartment of Immunoregulation; Institute of Medical Science; Tokyo Medical University ; Tokyo, Japan.
Mingli XuDepartment of Immunoregulation; Institute of Medical Science; Tokyo Medical University ; Tokyo, Japan.
Ren TsunodaDepartment of Immunoregulation; Institute of Medical Science; Tokyo Medical University ; Tokyo, Japan.
Kaname HiguchiDepartment of Immunoregulation; Institute of Medical Science; Tokyo Medical University ; Tokyo, Japan.
Takayuki YoshimotoDepartment of Immunoregulation; Institute of Medical Science; Tokyo Medical University ; Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since we first reported the antitumor efficacy of IL-27 in 2004, accumulating evidence obtained by several groups using a variety of preclinical mouse models indicates that IL-27 possesses potent antitumor activity against various types of tumors through multiple mechanisms depending on the characteristics of individual tumors without apparent adverse effects.

Indexed as

antitumorIL-27poly(I:C)TLR3TRAIL

Identifiers

PMID26451308
PMCPMC4589049

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.